Clinical trial · Observational
Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer
Molecular Metastasis in Lymph Nodes is Associated With Survival of Patients With Stage I NSCLC
NCT04266691CI-TRIAL-00043360completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Analysis of driver gene variation in early stage non-small cell lung cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| nonIntervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Driver gene mutation-positive
- description
- Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation positive.
- interventionNames
- Other: nonIntervention
- label
- Driver gene mutation-negative
- description
- Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation negative.
- interventionNames
- Other: nonIntervention
Primary outcomes (3)
- measure
- Driver gene mutation frequency of early stage NSCLC
- timeFrame
- 2019
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Female or male, 18 years of age or older 2. Histologically or cytologically proven diagnosis of early stage NSCLC 3. The lesion was completely resected by radical surgery 4. Able to get tumor tissue sample 5. Complete information of clinicopathological , survival, recurrence and metastasis can be obtained through follow-up Exclusion Criteria: 1. Combine with other tumor type 2. The investigator judges the situation that may affect the clinical search process and results
References
Publications (1)
- DERIVEDTian Y, Lai Q, Zheng Y, Ying L, Wang C, Jin J, Huang M, Wu Y, Li H, Zhang J, Su D. Oncogenic Alterations in Histologically Negative Lymph Nodes Are Associated with Prognosis of Patients with Stage I Lung Adenocarcinoma. Cancers (Basel). 2022 Feb 6;14(3):824. doi: 10.3390/cancers14030824. PMID 35159091